NEW YORK, April 11 – Signaling its interest in entering the burgeoning structural proteomics sector, Bruker AXS of Madison, Wis., said Wednesday it completed a deal to acquire Delft Instruments’ Nonius crystallography business.
Financial terms of the deal were not disclosed.
“Nonius is an ideal fit for Bruker AXS and provides important resources to accelerate the development and marketing of our new life-science tools for high-throughput structural proteomics," Martin Haase, CEO of Bruker AXS, said in a statement. "Furthermore, this merger will also allow us to strengthen our product development and customer support for our existing customer base in chemical crystallography."
The deal is the second acquisition in the past week in the structural proteomics sector. Last week, X-ray crystallography company Structural Genomix of San Diego announced plans to acquire Prospect Genomics, a Belmont, Calif.-based company specializing in computational protein structure prediction.
Based in Delft, The Netherlands, Nonius, which had more than $8 million in revenues in 2000 and 42 employees, will house the company’s European center for X-ray crystallography. Lieuwe Boskma will continue to serve as managing director following the acquisition of the company, which will now be called Bruker Nonius.
Boskma said that the deal fit into the company’s plan to build its position in the X-ray crystallography market.
“Over the last year we had been looking into various strategic partnership options to strengthen our position in small-molecule crystallography, while accelerating the development of innovative structural proteomics solutions,” Boskma said. ”With investments from the Bruker AXS group, Bruker Nonius will be able to strengthen its position as a center of excellence for crystallography solutions, in collaboration with the well-established Bruker AXS crystallography group in Madison, Wisconsin.”
Bruker AXS develops life science and advanced materials research tools based on X-ray technology. The company, which is privately held, is controlled by the Laukien family, which also owns a majority stake in Bruker Daltonics. In 2000 Bruker AXS had revenues of more than $68 million.